StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) stock

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)

Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –

Vertex Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vertex Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $4.78B, up 21.8% year over year. For fiscal 2025 it was $4.17B. The highest annual figure on record is $4.31B in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.17B–
FY2024Dec 31, 2024-$232.90M-106.1%
FY2023Dec 31, 2023$3.83B-11.0%
FY2022Dec 31, 2022$4.31B+54.8%
FY2021Dec 31, 2021$2.78B-2.6%
FY2020Dec 31, 2020$2.86B+138.5%
FY2019Dec 31, 2019$1.20B+88.5%
FY2018Dec 31, 2018$635.15M+415.4%
FY2017Dec 31, 2017$123.24M+1140.4%
FY2016Dec 31, 2016$9.94M–
FY2015Dec 31, 2015-$466.88M–
FY2014Dec 31, 2014-$692.41M–
FY2013Dec 31, 2013-$610.01M-1405.5%
FY2012Dec 31, 2012$46.73M-58.9%
FY2011Dec 31, 2011$113.82M–
FY2010Dec 31, 2010-$696.08M–
FY2009Dec 31, 2009-$614.01M–
FY2008Dec 31, 2008-$462.71M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.25B+8.3%
Q1 FY2026Mar 31, 2026$1.14B+80.6%
Q4 FY2025Dec 31, 2025$1.21B+17.5%
Q3 FY2025Sep 30, 2025$1.19B+6.3%
Q2 FY2025Jun 30, 2025$1.15B–
Q1 FY2025Mar 31, 2025$630.10M-44.7%
Q4 FY2024Dec 31, 2024$1.03B+3.8%
Q3 FY2024Sep 30, 2024$1.12B+7.5%
Q2 FY2024Jun 30, 2024-$3.51B-442.4%
Q1 FY2024Mar 31, 2024$1.14B+46.3%
Q4 FY2023Dec 31, 2023$988.50M-4.4%
Q3 FY2023Sep 30, 2023$1.04B-7.9%
Q2 FY2023Jun 30, 2023$1.03B-7.2%
Q1 FY2023Mar 31, 2023$779.00M-25.2%
Q4 FY2022Dec 31, 2022$1.03B+17.8%
Q3 FY2022Sep 30, 2022$1.13B+6.8%
Q2 FY2022Jun 30, 2022$1.11B–
Q1 FY2022Mar 31, 2022$1.04B+17.2%
Q4 FY2021Dec 31, 2021$877.70M+17.7%
Q3 FY2021Sep 30, 2021$1.05B+56.9%
Q2 FY2021Jun 30, 2021-$37.90M-105.3%
Q1 FY2021Mar 31, 2021$887.80M+23.3%
Q4 FY2020Dec 31, 2020$745.79M+35.2%
Q3 FY2020Sep 30, 2020$672.24M+576.8%
Q2 FY2020Jun 30, 2020$718.03M+166.0%
Q1 FY2020Mar 31, 2020$720.22M+160.2%
Q4 FY2019Dec 31, 2019$551.47M+331.8%
Q3 FY2019Sep 30, 2019$99.33M-51.7%
Q2 FY2019Jun 30, 2019$269.96M+56.2%
Q1 FY2019Mar 31, 2019$276.81M+114.7%
Q4 FY2018Dec 31, 2018$127.72M+1.6%
Q3 FY2018Sep 30, 2018$205.65M–
Q2 FY2018Jun 30, 2018$172.88M+228.0%
Q1 FY2018Mar 31, 2018$128.90M-52.4%
Q4 FY2017Dec 31, 2017$125.74M+217.2%
Q3 FY2017Sep 30, 2017-$326.04M–
Q2 FY2017Jun 30, 2017$52.71M–
Q1 FY2017Mar 31, 2017$270.84M–
Q4 FY2016Dec 31, 2016$39.64M–
Q3 FY2016Sep 30, 2016-$18.73M–

More Vertex Pharmaceuticals figures

See a number that looks wrong?